How to access Ingrezza from India — the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-24

An Indian patient with tardive dyskinesia (TD) — or, per expanded labelling, chorea associated with Huntington's disease — may receive a prescription for Ingrezza (valbenazine) from their treating neurologist or psychiatrist. Ingrezza is FDA-approved for both indications, developed by Neurocrine Biosciences. It is not a controlled substance. In India, Ingrezza is not routinely registered for domestic outpatient dispensing, and access is typically coordinated through the named-patient import pathway under the Central Drugs Standard Control Organisation (CDSCO) framework.

This guide explains the pathway, documentation your physician prepares, typical timing and cost bands, and where Reserve Meds fits in.

The clinical situation

Ingrezza is an oral vesicular monoamine transporter 2 (VMAT2) inhibitor taken once daily, typically starting at 40 mg and titrated to 60 or 80 mg based on response and tolerability. The once-daily dosing profile is a convenience differentiator within the VMAT2-inhibitor class (deutetrabenazine is dosed twice daily).

Eligibility for tardive dyskinesia requires documented exposure to dopamine receptor-blocking agents — typically antipsychotics — and persistent involuntary movements. Eligibility for Huntington's chorea requires genetic confirmation and a movement-disorder workup. Your neurologist or psychiatrist will establish baseline using the Abnormal Involuntary Movement Scale (AIMS) for TD or the Unified Huntington's Disease Rating Scale chorea score for Huntington's, screen for depression and suicidality (labelled warning for Huntington's patients), review QT interval (labelled QT-prolongation monitoring), and check hepatic function. Monitoring continues during titration and at subsequent visits.

Is Ingrezza legally importable into India?

Yes — through the CDSCO personal-import / named-patient framework administered under the Drugs and Cosmetics Rules. The mechanism permits import of an unregistered medicine for a specific named patient when (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent registered alternative is suitable for the patient, (c) a qualified Indian physician accepts clinical responsibility, and (d) chain of custody is documented. Both tardive dyskinesia and Huntington's chorea have limited disease-specific registered options in India, which is why named-patient imports are frequently used.

How the pathway works, step by step

1. Consultation with your treating neurologist or psychiatrist. Indication documentation (TD exposure history or Huntington's genetic confirmation), movement-disorder scale baseline, and clinical rationale.
2. Baseline assessment. AIMS or UHDRS-chorea baseline, depression/suicidality screen (for Huntington's patients), ECG for QT review, hepatic function.
3. CDSCO named-patient application. The physician or hospital pharmacy files clinical rationale, patient reference, titration plan, and chain-of-custody commitment.
4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Ingrezza from authorised distribution under DSCSA.
5. Ambient shipment. Ingrezza ships under controlled ambient conditions with chain-of-custody documentation.
6. Arrival and dispensing. The hospital pharmacy releases the bottle with titration and monitoring guidance.

What documentation your physician needs

• Clinical rationale letter confirming indication (TD or Huntington's chorea) and Ingrezza as the indicated therapy
• Verification of Indian medical registration (NMC / state council)
• AIMS score or UHDRS-chorea baseline
• Genetic confirmation report (for Huntington's)
• Depression/suicidality screen (for Huntington's patients, per labelling)
• Baseline ECG for QT interval and hepatic function tests
• Planned titration schedule and monitoring plan

Reserve Meds provides a physician documentation kit bundling templates CDSCO reviewers expect for movement-disorder named-patient imports.

Typical costs and indicative timing

Ingrezza's US cash-pay reference cost sits in an indicative 2026 annual range of roughly USD 85,000–110,000 depending on titrated dose. International logistics, CDSCO documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake. These figures are indicative drug-only reference pricing, not guaranteed.

Indicative timing — not guaranteed — for first dispense after cohort intake opens is approximately 7–14 days from the moment a complete CDSCO application is submitted. Monthly refills are generally faster once the pathway is established.

Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.

Reserve Meds's role

• Sourcing. Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
• Documentation. Regulatory package for your physician and CDSCO review.
• Logistics. Ambient-controlled shipment to your prescribing hospital pharmacy.
• Concierge case lead. A named point of contact coordinating monthly refills.

What we do not do: we are not the prescriber, do not practise medicine, and are not the dispensing pharmacy. All clinical decisions remain with your treating physician. We operate on a waitlist basis during pre-launch.

Frequently asked

Is this legal in India? Yes, when executed through the CDSCO named-patient / personal-import framework with appropriate documentation. See our trust and compliance page.

Is Ingrezza a controlled substance? No. Valbenazine is not a scheduled controlled substance.

How does Ingrezza compare with Austedo? Both are VMAT2 inhibitors for movement-disorder indications. Ingrezza is typically dosed once daily; Austedo is dosed twice daily (immediate-release) or once daily (Austedo XR). Your physician selects based on the specific indication, titration tolerability, and monitoring profile.

What is the suicidality warning? Ingrezza carries a labelled warning regarding depression and suicidal ideation/behaviour in Huntington's disease patients. Structured screening before and during therapy is required.

Why QT monitoring? VMAT2 inhibitors can prolong the QT interval in susceptible patients. A baseline ECG and avoidance in patients with significant QT prolongation or concurrent QT-prolonging medications is part of standard initiation.

Will private insurance cover this? Cash-pay is the default. Some Indian private insurers consider named-patient imports case by case; we supply documentation but do not process claims directly.

Next step — join the first-cohort waitlist

Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we enter intake for Ingrezza coordination in India.

Add me to the Ingrezza waitlist

Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.

---

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are in pre-launch; service availability is limited to our first cohort and published timelines are indicative, not guarantees. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.

Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-24.